Genotypic and phenotypic changes during culture of a multinucleoside- resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 12, 1996, Pages 2887-2890

  Shafer, Robert W ^a   Winters, Mark A ^a   Iversen, Astrid K N ^a   Merigan, Thomas C ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS CULTURE; VIRUS MUTATION;

EID: 0029838019     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.12.2887     Document Type: Article

References (28)

1. Boucher, C. A., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
2. Boyer, P. L., C. Tantillo, A. Jacob-Molina, R. G. Nanni, J. Ding, E. Arnold, and S. H. Hughes. 1994. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length: the sensitivity of drug-resistant mutants does not. Proc. Natl. Acad. Sci. USA 91:4882-4886.
3. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
4. Eron, J. J., S. L. Benoit, J. Jemsek, R. D. MacArthur, J. Santana, J. B. Quinn, D. R. Kuritzkes, M. A. Fallon, and M. Rubin. 1995. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N. Engl. J. Med. 333:1662-1669.
5. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. A. Wainberg. 1992. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J. Virol. 66:7128-7135.
6. Iversen, A. K. N., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug-resistant HIV-1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
7. Jacob-Molina, A., J. Ding, R. G. Nanni, A. D. Clark, Jr., X. Lu, C. Tantillo, R. Williams, G. Kamer, A. L. Ferris, and P. Clark. 1993. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl. Acad. Sci. USA 90:6320-6324.
8. Kavlick, M. F., T. Shirasaka, E. Kojima, J. M. Pluda, F. Hui, R. Yarchoan, and H. Mitsuya. 1995. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving 2′,3′-dideoxy-3′-thiacytidine. Antiviral Res. 28:133-146.
9. Klimpton, J., and M. Emerman. 1992. Detection of replication competent and pseudotyped HIV with a sensitive cell line based on activation of an integrated beta-galactosidase gene. J. Virol. 66:2232-2239.
10. Larder, B. A. 1992. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36:2664-2669.
11. Larder, B. A. 1994. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol. 75:951-957.
12. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism of sustained antiviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
13. Larder, B. A., A. Kohli, S. Bloor, S. D. Kemp, P. R. Harrigan, R. T. Schooley, J. M. A. Lange, K. N. Pennington, M. H. St. Clair, and the Protocol 34,225-02 Collaborative Group. 1996. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′,3′-dideoxyinosine or AZT plus 2′,3′-dideoxycytidine combination therapy. J. Virol. 70:5922-5929.
14. Maeda, Y., T. Ueno, M. F. Kavlick, T. Shirasaka, R. Yarchoan, and H. Mitsuya. 1996. Emergence of multi-dideoxynucleoside-resistant HIV-1 in patients receiving long-term combination therapy with dideoxynucleosides. abstr. 40. In Program and abstracts of the 5th International Workshop on HIV Drug Resistance. MediTech Media Ltd., London.
15. Nijhuis, M., C. A. B. Boucher, and R. Schuurman. 1995. Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. BioTechniques 19:178-182.
16. Richman, D., C. K. Shin, I. Lowy, J. Rose, P. Prodanovich, S. Goff, and J. Griffin. 1991. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 88:11241-11245.
17. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C.-K. Shih, M. Myers, and J. Griffin. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
18. Schmit, J.-C., J. Cogniaux, P. Hermans, C. Van Vaeck, S. Sprecher, B. Van Remoortel, M. Witvrouw, J. Balzarini, J. Desmyter, E. De Clerq, and A.-M. Vandamme. 1996. Multiple drug resistance to nucleoside analogues and non-nucleoside reverse transcriptase inhibitors in an efficiently replicating HIV-1 patient strain. J. Infect. Dis. 174:962-968.
19. Schmit, J.-C., I. Vanderlinden, L. Ruiz, B. Clotet, P. Hermans, S. Sprecher, V. Arendt, W. Peetermans, T. Harrer, D. Vaira, J. Desmyter, E. De Clerq, and A.-M. Vandamme. 1996. Prevalence of multi-drug resistance to dideoxynucleoside (ddN) analogues in patients on ddN combination therapy, abstr. 39. In Program and abstracts of the 5th International Workshop on HIV Drug Resistance. Meditech Media Ltd., London.
20. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, and C. Christopherson. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
21. Shafer, R. W., A. K. Iversen, M. A. Winters, E. Aguiniga, D. A. Katzenstein, and T. C. Merigan. 1995. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J. Infect. Dis. 172:70-78.
22. Shafer, R. W., M. J. Kozal, D. A. Katzenstein, W. H. Lipil, I. F. Johnstone, and T. C. Merigan. 1993. Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates. J. Virol. Methods 41:297-310.
23. Shafer, R. W., M. J. Kozal, M. A. Winters, A. K. Iversen, D. A. Katzenstein, M. V. Ragni, W. A. Meyer, 3rd, P. Gupta, S. Rasheed, R. Coombs, M. Katzman, S. Fiscus, and T. C. Merigan. 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169:722-729.
24. Shirasaka, T., M. F. Kavlick, T. Ueno, W. Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
25. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
26. Tantillo, C., J. Ding, A. Jacobo-Molina, R. G. Nanni, P. L. Boyer, S. H. Hughes, R. Pauwels, K. Andries, P. A. Janssen, and E. Arnold. 1994. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 243:369-387.
27. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
28. Ueno, T., T. Shirasaka, and H. Mitsuya. 1995. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2,3,-dideoxynucleoside 5′-triphosphates. J. Biol. Chem. 270:23605-23611.